Hexarad, a pioneering radiology tech startup based in London, has successfully raised €13 million in a new funding round. This significant investment marks a pivotal step forward in addressing the mounting radiology backlogs within the NHS.
Strategic Investment Leadership
In this recent funding round, Hexarad attracted key investment from European healthtech growth firm MTIP, a notable player in the industry. MTIP’s portfolio includes investments in innovative health companies such as Apricity. Their participation in Hexarad’s growth signifies confidence in the startup’s potential to revolutionise radiology services.
Existing investor, Foresight Group, which has previously supported the company, also contributed to this funding round. Their continued backing underscores the remarkable progress Hexarad has made since its inception. As Hexarad strengthens its technological capabilities, the company’s influence within the health tech sector is poised for further expansion.
Advancements in Radiology Solutions
Founded in 2016 by a team of NHS radiologists, Hexarad offers cutting-edge technologies to enhance radiology efficiency across the UK, Ireland, and beyond. Its proprietary software and teleradiology platform are pivotal in expanding radiology capacities and addressing diagnostic delays.
The company’s innovative auto-allocation tool is particularly noteworthy, providing rapid and accurate scan assignments. This tool is 90% faster than manual methods, a significant improvement that enhances both speed and accuracy in diagnostic processes. Such technological advancements position Hexarad as a leader in healthcare innovation.
Expanding the Radiology Community
Hexarad has successfully cultivated a thriving community of over 200 radiologists on its platform.
This strong network underscores its commitment to delivering high-quality services and fostering professional development among radiologists. With industry-leading turnaround times, Hexarad consistently achieves high satisfaction scores from its users.
The substantial growth of this community serves to further enhance the platform’s capabilities. By fostering collaboration and knowledge sharing, Hexarad continues to advance its technology and services, setting new benchmarks within the industry.
Innovative Leadership Team
Led by a talented team including Dr. Amy Davis and CEO Dr. Farzana Rahman, Hexarad’s leadership is steeped in clinical expertise. Their firsthand experience with NHS challenges uniquely positions them to drive effective solutions.
Dr. Rahman highlights the strategic importance of this funding, noting that their mission focuses on tackling the global shortage of radiologists. Such leadership insight differentiates Hexarad within the competitive health tech landscape.
Future Growth Trajectory
This fresh injection of €13 million will bolster Hexarad’s plans for international expansion. The funding will enable further development of their technology and extend their market reach.
Hexarad aims to cement its status as a foremost health tech enterprise, enhancing its capacity to offer innovative solutions on a global scale. Such ambitions reflect a forward-thinking approach to healthcare challenges.
Commitment to Patient-Centric Care
Dr. Rahman emphasises the commitment to patient care as a driving force in Hexarad’s operations. This patient-first philosophy ensures that technological advancements directly improve patient outcomes.
As Hexarad continues to integrate clinical needs into its strategic framework, its solutions remain robust, effective, and aligned with the core values of healthcare delivery.
Conclusion
Hexarad’s strategic expansion, supported by substantial funding and a commitment to innovation, positions the company as a transformative force in radiology technology.
The investment not only highlights confidence in Hexarad’s capabilities but also underscores a broader industry trend towards innovative solutions in healthcare. With a visionary leadership team at its helm, Hexarad is set to redefine radiology services across multiple regions.
